These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 29385160)

  • 1. Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.
    Just S; Chenard BL; Ceci A; Strassmaier T; Chong JA; Blair NT; Gallaschun RJ; Del Camino D; Cantin S; D'Amours M; Eickmeier C; Fanger CM; Hecker C; Hessler DP; Hengerer B; Kroker KS; Malekiani S; Mihalek R; McLaughlin J; Rast G; Witek J; Sauer A; Pryce CR; Moran MM
    PLoS One; 2018; 13(1):e0191225. PubMed ID: 29385160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Treatment with a Novel TRPC4/C5 Channel Inhibitor Produces Antidepressant and Anxiolytic-Like Effects in Mice.
    Yang LP; Jiang FJ; Wu GS; Deng K; Wen M; Zhou X; Hong X; Zhu MX; Luo HR
    PLoS One; 2015; 10(8):e0136255. PubMed ID: 26317356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased anxiety-like behavior and Gαq/11-dependent responses in the amygdala of mice lacking TRPC4 channels.
    Riccio A; Li Y; Tsvetkov E; Gapon S; Yao GL; Smith KS; Engin E; Rudolph U; Bolshakov VY; Clapham DE
    J Neurosci; 2014 Mar; 34(10):3653-67. PubMed ID: 24599464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and optimization of 2-aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels.
    Zhu Y; Lu Y; Qu C; Miller M; Tian J; Thakur DP; Zhu J; Deng Z; Hu X; Wu M; McManus OB; Li M; Hong X; Zhu MX; Luo HR
    Br J Pharmacol; 2015 Jul; 172(14):3495-509. PubMed ID: 25816897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRPC4 and TRPC5: receptor-operated Ca2+-permeable nonselective cation channels.
    Plant TD; Schaefer M
    Cell Calcium; 2003; 33(5-6):441-50. PubMed ID: 12765689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels.
    Jiang H; Zeng B; Chen GL; Bot D; Eastmond S; Elsenussi SE; Atkin SL; Boa AN; Xu SZ
    Biochem Pharmacol; 2012 Apr; 83(7):923-31. PubMed ID: 22285229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent, selective, and subunit-dependent activation of TRPC5 channels by a xanthine derivative.
    Minard A; Bauer CC; Chuntharpursat-Bon E; Pickles IB; Wright DJ; Ludlow MJ; Burnham MP; Warriner SL; Beech DJ; Muraki K; Bon RS
    Br J Pharmacol; 2019 Oct; 176(20):3924-3938. PubMed ID: 31277085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticolimbic expression of TRPC4 and TRPC5 channels in the rodent brain.
    Fowler MA; Sidiropoulou K; Ozkan ED; Phillips CW; Cooper DC
    PLoS One; 2007 Jun; 2(6):e573. PubMed ID: 17593972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRPC1 as a negative regulator for TRPC4 and TRPC5 channels.
    Kim J; Ko J; Myeong J; Kwak M; Hong C; So I
    Pflugers Arch; 2019 Aug; 471(8):1045-1053. PubMed ID: 31222490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action.
    Andreasen JT; Fitzpatrick CM; Larsen M; Skovgaard L; Nielsen SD; Clausen RP; Troelsen K; Pickering DS
    Brain Res; 2015 Mar; 1601():117-26. PubMed ID: 25578259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for human TRPC5 channel inhibition by two distinct inhibitors.
    Song K; Wei M; Guo W; Quan L; Kang Y; Wu JX; Chen L
    Elife; 2021 Mar; 10():. PubMed ID: 33683200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteromeric channels formed by TRPC1, TRPC4 and TRPC5 define hippocampal synaptic transmission and working memory.
    Bröker-Lai J; Kollewe A; Schindeldecker B; Pohle J; Nguyen Chi V; Mathar I; Guzman R; Schwarz Y; Lai A; Weißgerber P; Schwegler H; Dietrich A; Both M; Sprengel R; Draguhn A; Köhr G; Fakler B; Flockerzi V; Bruns D; Freichel M
    EMBO J; 2017 Sep; 36(18):2770-2789. PubMed ID: 28790178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiolytic and antidepressant-like activities of the novel and potent non-imidazole histamine H₃ receptor antagonist ST-1283.
    Bahi A; Schwed JS; Walter M; Stark H; Sadek B
    Drug Des Devel Ther; 2014; 8():627-37. PubMed ID: 24920886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tonantzitlolone is a nanomolar potency activator of transient receptor potential canonical 1/4/5 channels.
    Rubaiy HN; Ludlow MJ; Siems K; Norman K; Foster R; Wolf D; Beutler JA; Beech DJ
    Br J Pharmacol; 2018 Aug; 175(16):3361-3368. PubMed ID: 29859013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A benzothiadiazine derivative and methylprednisolone are novel and selective activators of transient receptor potential canonical 5 (TRPC5) channels.
    Beckmann H; Richter J; Hill K; Urban N; Lemoine H; Schaefer M
    Cell Calcium; 2017 Sep; 66():10-18. PubMed ID: 28807145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor subtype 4 activation is involved in anxiety and depression-like behavior in mouse models.
    Scheich B; Gaszner B; Kormos V; László K; Ádori C; Borbély É; Hajna Z; Tékus V; Bölcskei K; Ábrahám I; Pintér E; Szolcsányi J; Helyes Z
    Neuropharmacology; 2016 Feb; 101():204-15. PubMed ID: 26387439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRPC5.
    Zholos AV
    Handb Exp Pharmacol; 2014; 222():129-56. PubMed ID: 24756705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
    Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
    Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xiaochaihutang attenuates depressive/anxiety-like behaviors of social isolation-reared mice by regulating monoaminergic system, neurogenesis and BDNF expression.
    Ma J; Wang F; Yang J; Dong Y; Su G; Zhang K; Pan X; Ma P; Zhou T; Wu C
    J Ethnopharmacol; 2017 Aug; 208():94-104. PubMed ID: 28687505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.
    Chaki S; Hirota S; Funakoshi T; Suzuki Y; Suetake S; Okubo T; Ishii T; Nakazato A; Okuyama S
    J Pharmacol Exp Ther; 2003 Feb; 304(2):818-26. PubMed ID: 12538838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.